Recce Pharmaceuticals achieved a milestone as the State of Israel Patent Office granted a new Patent Family 4 for its anti-infectives, RECCE 327 and RECCE 529, extending until 2041.

The patent covers the preparation process and usage of these anti-infectives for treating various bacterial and viral infections.

It marks Recce's first patent in Israel, a country with a thriving pharmaceutical market valued at US$5.3 billion ($8.14 billion) in 2021.

The development highlights the potential of Recce's products in combating antibiotic-resistant pathogens and emerging viral diseases globally.